Collectively, these data demonstrate that SATB2 disruption potently suppresses the GSC‐driven tumor growth, indicating that SATB2 is critical for maintaining the tumorigenic potential of GSCs in vivo. The gene discussed is SATB2; the disease is neoplasm.